Syringomyelia detected in both animals and humans may cause a variable degree of discomfort and its etiology is commonly unidentified. The aim of this study was to compare the outcome in dogs with those having syringomyelia of different etiology. Dogs with syringomyelia were subdivided into two groups: syringomyelia associated with Chiari-like malformation (S-CLM) (15 dogs) and syringomyelia of other etiology (SOA) (15 dogs). Age onset of S-CLM clinical signs was earlier compared to SOA (mean S-CLM and SOA values: 50.53 and 97.6 months, respectively, p = 0.021). Two neurological dysfunction scoring systems alongside nociception values were lower in SOA compared to S-CLM (mean values for neurological dysfunction scoring system SOA and S-CLM: 5.87 and 4.2, respectively, p = 0.032) (mean values for nociception SOA and S-CLM: 20.97 and 10.03, respectively, p = 0.03). Symptomatic therapy included combinations of corticosteroids, gabapentin (10/15, 66.6%) in S-CLM and NSAID +/− gabapentin (8/15, 53.3% and 9/15, 60%, respectively) in SOA dogs. Eight S-CLM dogs (53.4%) improved with symptomatic therapy and eleven were still alive; however, most SOA dogs (9/15, 73.4%) died/were euthanized by the end of this study. SOA dogs demonstrated more severe neurological signs compared to S-CLM, although the outcome between the two groups was not associated (p = 0.211).
Syringomyelia detected in both animals and humans may cause variable degree of dis-comfort and its etiology is commonly unidentified. The aim of the study was to compare the outcome in dogs with syringomyelia of different etiology. Dogs with syringomyelia were subdivided into two groups: A: Syringomyelia associated with Chiari-like malfor-mation (S-CLM) (15 dogs) and B: syringomyelia of other etiology (SOA) (15 dogs). Age on-set of S-CLM clinical signs was earlier compared to SOA (mean S-CLM and SOA values: 50.53 and 97.6 months, respectively, p=0.021). Two neurological dysfunction scoring sys-tems alongside with nociception values were lower in SOA compared to S-CLM (mean values for neurological dysfunction scoring system SOA and S-CLM: 5.87 and 4.2, respec-tively, p=0.032) (mean values for nociception SOA and S-CLM: 20.97 and 10.03, respec-tively, p=0.03). Symptomatic therapy included combinations of corticosteroids, gabapen-tin (10/15, 66.6%) in S-CLM and NSAID +/- gabapentin (8/15, 53.3% and 9/15, 60%, respec-tively) in SOA dogs. Eight S-CLM dogs (53.4%) improved with symptomatic therapy and 11 were still alive however most SOA dogs (9/15, 73.4%) died/were euthanized by the end of the study. SOA dogs demonstrated more severe neurological signs compared to S-CLM, although outcome between the two groups was not associated (p=0.211).
Introduction: Resistant epileptic episodes, such as refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE), are neurological emergencies that require immediate medical treatment. Although inhalational anesthetics, such as isoflurane (ISO), have been proposed as a means of seizure control in dogs, there is currently a lack of both experimental and clinical studies on this subject.Study design: This is a retrospective clinical study.Methods: Records of dogs that received ISO for the management of RSE and SRSE during their intensive care unit (ICU) hospitalization at the Companion Animal Clinic of the Aristotle University of Thessaloniki were included in the present study. The study period spanned from February 2013 to March 2023. Dogs were identified as responders (R) when RSE/SRSE ceased after ISO administration, and the dogs were successfully discharged from the ICU after ISO discontinuation. Dogs were identified as non-responders (NR) when RSE/SRSE ceased after ISO administration, but RSE/SRSE reoccurred after ISO discontinuation. Additional data about the number and time of ISO cycles, the time of ICU hospitalization, the side effects of ISO administration, and an additional administration of antiepileptic drugs (AEDs) and anesthetic drugs were also recorded.Results: A total of 20 dogs with 26 recorded RSE/SRSE episodes and 26 anesthetic cycles with ISO were included in the present study. The clinical termination of seizure activity was achieved 100% (26/26) in all episodes. In 73.1% (19/26) of the episodes, ISO administration resulted in successful RSE/SRSE treatment. Poor outcome was recorded in 26.9% (7/26) of the episodes because RSE/SRSE reoccurred after ISO discontinuation, and the dogs were euthanatized or died due to cardiac arrest. Inspiratory ISO ranged between 0.5 and 4.0%. The median time of the anesthetic cycles with ISO was 12.67 h (4.00–62.00). The median duration of the ICU hospitalization was 48.00 h (24.00–120.00). At least one ISO-related side effect was recorded in 23 out of 26 (88.5%) episodes.Conclusion: To the authors’ knowledge, this is the first clinical study that addresses the administration of ISO for RSE/SRSE treatment in dogs. The use of ISO may be beneficial in terminating RSE/SRSE; however, further prospective studies are necessary to confirm this observation.
14 February 2025 in Journal of Feline Medicine and Surgery
Objectives: The aim of this study was to evaluate and describe airgun spinal cord injuries (SCIs) in cats. Methods: Records of cats presented at the Companion Animal Clinic of Aristotle University of Thessaloniki with neurological deficits associated with a 4.5 mm airgun projectile (AGP) SCI were included. Only cats with lodged projectiles in the spinal canal were included in the present study. Cats were categorised into groups according to the neurological grade, management, season of presentation and projectile location. Results: A total of 23 cats were included in this retrospective study. There were one cervical (C), 17 thoracolumbar (T) and five lumbosacral (L) airgun SCIs. The presence of the projectile in the spinal canal was confirmed by radiographic imaging. Of the cases, 44% were presented in autumn, which was the most frequently presenting season. Surgical management was elected in 20/23 (87%) of the cats, 1/23 (4.3%) were managed conservatively and 2/23 (8.7%) were euthanased owing to poor prognosis without treatment. The neurological grades were V and III in 83% and 4% of the cats, respectively. The remaining cats (13%) had asymmetrical neurological deficits. Conscious movement was regained in 30% of surgically treated cats; spinal walking in 20% and 50% were unimproved. Micturition restoration was not observed in most of the cases. Conclusions and relevance: Airgun spinal injuries result in severe mobility and micturition disorders in cats. As a result of the small sample size, it is uncertain whether the outcome may be influenced by surgical or conservative management.
Background: The purpose of this study is to evaluate differences in transdiaphragmatic pressure (Pdi) in dogs suffering from cervical myelopathy (CM) and thoracolumbar myelopathy (TLM) anaesthetised with isoflurane (ISO). Methods: This prospective cohort study included ASA II-status dogs diagnosed with either CM or TLM, anaesthetised for diagnostic or surgical purposes between September 2021 and July 2023. Patients followed the same anaesthetic protocol, and maximum Pdi was recorded at 10 (Pdimax10), 20 (Pdimax20), and 30 (Pdimax30) minutes using balloon catheters placed in the stomach (Pgast) and in the mid-third of the oesophagus (Poes). Results: A total of 50 dogs were included: 25 in the CM group and 25 in the TLM group. In the TLM group, Pdimax10 was 9.4 mmHg ± 6.1, and in the CM group, it was 7.2 mmHg ± 4.6 (p = 0.167). Pdimax20 was 10.2 mmHg ± 5.8 in the TLM group and 8 mmHg ± 5.1 in the CM group (p = 0.155). Pdimax30 was 9.2 mmHg ± 5.5 in the TLM group and 8.1 mmHg ± 5.5 in the CM group (p = 0.479). Conclusions: The findings suggest that diaphragmatic contractility is similar in dogs with CM and TLM under ISO anaesthesia.
Background: The aim of the present retrospective observational study is to compare the required doses of propofol (PPF) for anaesthesia induction in dogs presented with intervertebral disc disease (IVDD)-related thoracolumbar or cervical myelopathy. Methods: The anaesthetic records of dogs with either cervical- or thoracolumbar-related myelopathy anaesthetised for diagnostic or surgical procedures from September 2021 to July 2023 were evaluated. Inclusion criteria were premedication with the same dose of dexmedetomidine (DEX) (180 μg m−2), and induction with PPF. The sedation score (SS), Glasgow Composite Measure Pain Scale-Short Form (GCMPS-SF) results and the total PPF dose required for intubation were collected. Data were analysed with the Shapiro–Wilk test, independent samples t-test and Spearman’s rho test. A value of p < 0.05 was considered statistically significant. Results: Fifty-five records were included in the study, 27 dogs with cervical and 28 with thoracolumbar myelopathy due to IVDD. Statistically significant higher doses of PPF were required in the dogs with cervical (mean 3.2 mg kg−1, ±SD 1.25 mg kg−1) than with thoracolumbar (mean 1.9 mg kg−1, ±SD 0.65 mg kg−1) myelopathy (t-test, p < 0.001). The SS in the dogs with cervical–cervicothoracic myelopathy (CCTM) (median 6, ±min 2 max 10) also differed from the SS of the dogs with thoracolumbar myelopathy (TLM) (median 7.5, min 2 max 12) (t-test, p = 0.02). Sedation score and the dose of PPF were significantly negatively correlated (Spearman’s rho −0.311, p = 0.021). Sedation score and GCMPS-SF were also significantly negatively correlated (Spearman’s rho −0.363, p = 0.007). However, no statistically significant negative correlation was found between PPF dose and GCMPS-SF score (Spearman’s rho = 0.248, p = 0.068). Conclusions: Our findings should be considered when planning anaesthetic protocols in patients suffering from IVVD-related myelopathy in order to optimize safety in these patients.